Abstract
During the development of antimicrobial peptides (AMP) as potential therapeutics, antimicrobial susceptibility testing (AST) stands as an essential part of the process in identification and optimisation of candidate AMP. Standard methods for AST, developed almost 60 years ago for testing conventional antibiotics, are not necessarily fit for purpose when it comes to determining the susceptibility of microorganisms to AMP. Without careful consideration of the parameters comprising AST there is a risk of failing to identify novel antimicrobials at a time when antimicrobial resistance (AMR) is leading the planet toward a post-antibiotic era. More physiologically/clinically relevant AST will allow better determination of the preclinical activity of drug candidates and allow the identification of lead compounds. An important consideration is the efficacy of AMP in biological matrices replicating sites of infection, e.g., blood/plasma/serum, lung bronchiolar lavage fluid/sputum, urine, biofilms, etc., as this will likely be more predictive of clinical efficacy. Additionally, specific AST for different target microorganisms may help to better predict efficacy of AMP in specific infections. In this manuscript, we describe what we believe are the key considerations for AST of AMP and hope that this information can better guide the preclinical development of AMP toward becoming a new generation of urgently needed antimicrobials.
Introduction
We are currently entering a "post-antibiotic era" driven by rising antimicrobial resistance (AMR). Antimicrobial peptides (AMPs)—short, usually positively charged proteins that disrupt microbial membranes—are a promising solution to this crisis. However, a significant "translation gap" exists: many AMPs that show potent activity in laboratory settings fail during clinical trials. This discrepancy is largely attributed to the fact that gold-standard protocols for testing drug efficacy, established by bodies such as CLSI and EUCAST, were designed decades ago for traditional small-molecule antibiotics and do not account for the unique physicochemical properties of peptides.
The Mechanism of Action
AMPs typically function by interacting with and disrupting the microbial lipid bilayer. Understanding these interactions is crucial for designing effective testing protocols.
As shown in the models above, AMPs can disrupt membranes through various mechanisms, such as the "carpet model" or the formation of discrete pores. Because these interactions are often driven by charge and hydrophobicity, the environment in which they are tested—including the presence of other ions or surfaces—can drastically alter their perceived efficacy.
The Limitations of Standard AST
The current "one size fits all" approach to AST often leads to the premature dismissal of effective drug candidates. Standard Mueller-Hinton Broth (MHB), while excellent for traditional antibiotics, is high in salts and anionic amino acids that can precipitate peptides or mask their activity. Furthermore, standard tests utilize bacteria in their exponential growth phase, whereas real-world infections often involve biofilms or metabolically dormant "Small Colony Variants" (SCVs) that AMPs are uniquely suited to target.
Bridging the Translation Gap
To improve the predictive power of preclinical testing, researchers must move toward more physiologically relevant models. This involves accounting for factors that are present in the human body but absent in a standard plastic petri dish.
As summarized in the table above, moving from simple in vitro environments to complex ex vivo and in vivo models introduces a multitude of variables—such as biological matrices, metabolic interactions, and polypharmacy—that standard AST fails to capture.
Key Physiological Factors
- The "Plastic Problem": Many AMPs are cationic (positively charged) and tend to bind to the negatively charged polypropylene or glass surfaces of standard labware. This reduces the effective drug concentration and leads to an overestimation of the Minimum Inhibitory Concentration (MIC).
- Bicarbonate Interference: Bicarbonate is ubiquitous in human tissues but absent in standard media. It can dissipate the trans-membrane pH gradient of bacteria, making them significantly more susceptible to certain AMPs like LL-37.
- Media Composition: Testing in media that mimics the site of infection (e.g., synthetic sputum for cystic fibrosis) often yields results that differ by more than 20-fold compared to standard MHB.
Conclusion
The lack of standardized, modified protocols for AMP testing remains a primary hurdle in the clinical pipeline. While over 400 peptide-based drugs are in pre-clinical development, only about 15% of those that reach clinical trials currently succeed. To close this gap, there is an urgent need to standardize "physiological" AST, ensuring that additives like bicarbonate and the use of low-protein-binding materials become part of the official regulatory path. By adopting "fit-for-purpose" testing, we can better identify the next generation of life-saving antimicrobials.
Summary updated